Cost-effective Cancer Checks
How population testing of breast and ovarian gene mutations may be the way forward
William Aryitey |
Is screening the entire population a cost-effective way to detect breast cancer mutations? The answer, according to a study by a multi-institutional team of researchers, is yes. “I have been working in the area of population testing for the last 10 years, and there are few interventions in medicine that save both money and lives,” says Ranjit Manchanda, Clinical Senior Lecturer, and Consultant Gynecological Oncologist at Barts Cancer Institute. “We have previously shown in a randomized trial that population-based BRCA testing in a Jewish population is effective, acceptable, does not have detrimental effects on psychological well-being or quality of life, and is cost-effective. In fact, in most scenarios, it is cost-saving.”
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!